Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 31 AL 45

Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature

Islam MA, Khandker SS, Alam F, Khalil MI, Kamal MA, Gan SH.

Curr Top Med Chem. 2017;17(12):1408-1428. doi: 10.2174/1568026617666170103163054.

Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends

Bachurin SO, Bovina EV, Ustyugov AA.

Med Res Rev. 2017 Sep;37(5):1186-1225. doi: 10.1002/med.21434. Epub 2017 Jan 13.

Chronoinflammaging in Alzheimer; A systematic review on the roles of toll like receptor 2

Ravari A, Mirzaei T, Kennedy D, Kazemi Arababadi M.

Life Sci. 2017 Feb 15;171:16-20. doi: 10.1016/j.lfs.2017.01.003. Epub 2017 Jan 11.

Synaptic Plasticity, Dementia and Alzheimer Disease

Skaper SD, Facci L, Zusso M, Giusti P.

CNS Neurol Disord Drug Targets. 2017;16(3):220-233. doi: 10.2174/1871527316666170113120853.

The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind

Ricciarelli R, Fedele E.

Curr Neuropharmacol. 2017;15(6):926-935. doi: 10.2174/1570159X15666170116143743.

Update on Alzheimer's Disease Therapy and Prevention Strategies

Graham WV, Bonito-Oliva A, Sakmar TP.

Annu Rev Med. 2017 Jan 14;68:413-430. doi: 10.1146/annurev-med-042915-103753.

Management of Alzheimer's disease-An insight of the enzymatic and other novel potential targets

Islam BU, Tabrez S.

Int J Biol Macromol. 2017 Apr;97:700-709. doi: 10.1016/j.ijbiomac.2017.01.076. Epub 2017 Jan 19.

Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial

Reisberg B, Shao Y, Golomb J, Monteiro I, Torossian C, Boksay I, Shulman M, Heller S, Zhu Z, Atif A, Sidhu J, Vedvyas A, Kenowsky S.

Dement Geriatr Cogn Disord. 2017;43(1-2):100-117. doi: 10.1159/000455397. Epub 2017 Jan 26.

Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease

Giménez-Llort L, Ratia M, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Clos MV.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):124-131. doi: 10.1097/FBP.0000000000000292.

Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease

Wu WY, Dai YC, Li NG, Dong ZX, Gu T, Shi ZH, Xue X, Tang YP, Duan JA.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):572-587. doi: 10.1080/14756366.2016.1210139.

Neurogenic Traditional Chinese Medicine as a Promising Strategy for the Treatment of Alzheimer's Disease

Sreenivasmurthy SG, Liu JY, Song JX, Yang CB, Malampati S, Wang ZY, Huang YY, Li M.

Int J Mol Sci. 2017 Jan 28;18(2):272. doi: 10.3390/ijms18020272.

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease

Chase TN, Farlow MR, Clarence-Smith K.

Neurotherapeutics. 2017 Apr;14(2):405-416. doi: 10.1007/s13311-016-0511-x.

Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview

Kumar A, Singh A, Aggarwal A.

Indian J Exp Biol. 2017 Feb;55(2):63-73.

Potential benefits of phytochemicals against Alzheimer's disease

Wightman EL.

Proc Nutr Soc. 2017 May;76(2):106-112. doi: 10.1017/S0029665116002962. Epub 2017 Feb 1.

Exploration of Various Proteins for the Treatment of Alzheimer's Disease

Islam BU, Zaidi SK, Kamal MA, Tabrez S.

Curr Drug Metab. 2017;18(9):808-813. doi: 10.2174/1389200218666170203110135.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias